Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 11/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3270131 | 0.98 | PPARD (0.50) | PPARDPPARAPTGDR2MTNR1AMTNR1B | |
| SCHEMBL3270128 | 0.98 | PPARD (0.50) | PPARDPPARAPTGDR2MTNR1AMTNR1B | |
| SCHEMBL3276158 | 0.91 | PPARD (0.54) | PPARDPPARAPTGDR2PPARG | |
| SCHEMBL3270037 | 0.91 | PPARD (0.54) | PPARDPPARAPTGDR2PPARG | |
| SCHEMBL3268464 | 0.90 | PPARD (0.63) | PPARDPPARAPPARG | |
| SCHEMBL3271245 | 0.89 | PPARD (0.57) | PPARDPPARAPTGDR2 | |
| SCHEMBL3271243 | 0.89 | PPARD (0.54) | PPARDPPARAPTGDR2MTNR1AMTNR1B | |
| SCHEMBL3270950 | 0.89 | PPARD (0.62) | PPARDPPARAPTGDR2PPARG | |
| SCHEMBL3270089 | 0.88 | PPARD (0.53) | PPARDPPARAMTNR1AMTNR1BPKM | |
| SCHEMBL3269048 | 0.88 | PPARD (0.63) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558572-B1 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-30 | — | — | EP | claimed |
| US-7129268-B2 | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives | NOVO NORDISK A/S (DK) | 2006-10-31 | — | — | US | claimed |
| EP-1558572-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | claimed |
| US-20050070583-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2005-03-31 | — | — | US | claimed |
| WO-2004037776-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | claimed |
| EP-1558572-B1 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7129268-B2 | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives | NOVO NORDISK A/S (DK) | 2006-10-31 | — | — | US | disclosed |
| EP-1558572-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| US-20050070583-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2005-03-31 | — | — | US | disclosed |
| WO-2004037776-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070583-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PTGDR2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.